Most investors look at Bristol Myers Squibb, Merck, and Pfizer right now and see big dividends, cheap valuations, and stable cash flows. What they are not fully pricing in is what happens when those cash flows get cut in half.

The pharma patent cliff is not a future risk. It is happening now.

Between 2025 and 2030, more than $300 billion in prescription drug revenues will lose patent exclusivity. Nearly 200 drugs will see their patents expire in this window, including about 70 blockbusters generating over $1 billion each in annual sales. For context, the previous patent cliff, in 2016, eroded about $100 billion in brand-name sales. The current one is three times that size.

This is not a projection. The numbers are structural. They are patent expiration dates filed with the USPTO, not projections subject to debate. The consequences are predictable: branded drugs lose up to 80% of their revenue within the first year of facing generic or biosimilar competition.

Who Gets Hurt First

BMS is the clearest example of concentrated pain. The anticoagulant Eliquis remains one of the best-selling drugs in the world but is widely expected to face generic competition around 2028. Around the same timeframe, the cancer treatment Opdivo could also encounter biosimilar pressure in key markets. This duo generated combined worldwide sales of $24.5 billion last year, accounting for 51% of the company’s revenue. These are among the top-earning drugs going off patent, leaving BMS with the largest growth gap among its peers at about $38 billion.

With global sales of $14.4 billion in 2025, Eliquis ranks among the industry’s highest-grossing small molecules. Its exclusivity loss carries outsized revenue implications for BMS, with patent expiries expected this year for Europe and in 2027 for the US and Japan. Under the Inflation Reduction Act, a Medicare maximum fair price of $231 per 30-day supply took effect in January 2026, reducing net revenues two years ahead of the patent cliff. The global erosion is already underway. The US cliff is just delayed, not avoided.

Merck’s situation is arguably more complex. Keytruda generated $29.5 billion in sales in 2024 and has been reported to have crossed $30 billion in 2025, representing close to half of Merck’s total revenue. In its SEC risk disclosures, Merck has stated it expects US sales of Keytruda to decline beginning in January 2028 with IRA-related government pricing, and to further decline upon loss of market exclusivity following expiration of the US compound patent in December 2028.

Slight tangent, but it matters here: this is also why pharma M&A is accelerating so aggressively right now. Total pharma M&A deal value reached $240 billion in 2025, an 81% year-over-year increase, making it the strongest M&A year since 2019. ING projects 15% growth in both deal value and number of deals in 2026, forecasting nearly 520 deals totaling over $230 billion. The earnings hole created by these expiring franchises is forcing hand after hand across the entire sector.

The Part Wall Street Is Missing

The loser side of this trade is well-covered. What is not well-covered is who wins.

The pharmaceutical industry is undergoing a major shift as patent exclusivity expires for popular drugs. This opens up a $236 billion opportunity for generic and biosimilar manufacturers between 2025 and 2030. Generic manufacturers, biosimilar developers, and specialty pharma companies filing Paragraph IV certifications are sitting at the entry point of one of the largest revenue transfer events in the industry’s history.

Then there is Eli Lilly. The company delivered total revenue of $65.2 billion for full-year 2025, a 45% increase from $45 billion in 2024. The company also issued an optimistic financial outlook for 2026, forecasting revenue between $80 billion and $83 billion. Fueled by sales of its diabetes and obesity products, Eli Lilly is projected to become the world’s top-seller of prescription drugs by 2030. Analysts project Lilly’s diabetes treatment Mounjaro will be the world’s top-selling drug by then, generating $36 billion, while Zepbound is expected to rank third at $25.5 billion. Lilly is not just avoiding the cliff. It is building a completely separate mountain.

The year 2026 marks a major wave of pharmaceutical patent expirations, putting numerous blockbuster drugs spanning diabetes, immunology, cardiovascular, oncology, and other therapeutic areas on the verge of losing market exclusivity. Prominent examples include Merck’s diabetes franchises Januvia and Janumet, Pfizer’s immunology drug Xeljanz, and Novo Nordisk’s GLP-1 therapy Ozempic.

The Ozempic detail requires precision. In 2026, Novo Nordisk’s patent on semaglutide expired in several countries, including India and China, and generic-drug makers are poised to flood those markets with inexpensive products. But in Europe, the semaglutide compound benefits from supplementary protection certificates extending protection until March 2031, and in the United States, patent term extensions are expected to keep patent protection in place until at least 2032. The competitive dynamics are global but nuanced. The US revenue stream for Ozempic is not yet under the same near-term pressure as Eliquis or Keytruda.

Options Framework

For traders expecting continued pressure on BMS specifically, defined-risk structures using longer-dated puts capture the multi-year earnings erosion thesis without requiring a precise near-term catalyst. The April 2028 Eliquis loss-of-exclusivity date functions as a known anchor. IV in large-cap pharma remains historically compressed relative to the scale of coming earnings events, which makes long-dated protection relatively inexpensive on a cost-per-risk basis.

For traders with a bullish view on the generic beneficiaries, a basket approach across companies with high Paragraph IV pipeline exposure captures the revenue transfer without single-stock binary risk. Small-molecule drugs face a precipitous drop in sales, up to 90% within months, while biologics face a slower but still substantial erosion of 30 to 70% in the first year. That difference creates distinct strategic timelines depending on which side of the ledger you are on.

For investors with a longer horizon, Lilly’s decoupled growth profile makes it a structural long in a sector facing structural headwinds everywhere else. The valuation is not cheap. But analysts project Lilly’s prescription drug sales will reach $113 billion by 2030, well ahead of any of its large-cap pharma peers. That earnings trajectory is genuinely differentiated in a way that almost nothing else in the sector currently is.

The cliff is real. The question is just which side of it you are standing on.

Tactical Checklist

• BMS: Monitor Eliquis US loss-of-exclusivity (currently set for 2028) and European erosion already underway since May 2026. Watch IRA pricing impact on net revenue through 2027.
• Merck: Keytruda US compound patent expires December 2028. IRA pricing pressure begins January 2028. Subcutaneous Keytruda Qlex (approved September 2025) is the primary defensive play for extending exclusivity.
• Generic / Biosimilar beneficiaries: Paragraph IV filers across cardiovascular (Eliquis), oncology (Opdivo), and diabetes (Januvia) represent the highest-value entry points through 2028.
• Eli Lilly: Core incretin patents extend into the 2030s. 2026 revenue guidance of $80 to $83 billion reflects continued volume-driven growth largely insulated from the current loss-of-exclusivity cycle.
• Ozempic / Novo Nordisk: International patent erosion (India, China, Brazil) is active now. US protection holds to approximately 2032. Watch biosimilar litigation closely in European markets.
• Pharma M&A: Deal volume hit $240 billion in 2025. Mid-cap biotech valuations are being inflated by originator desperation to backfill revenue. Evaluate acquisition targets accordingly.